Tucatinib Alternatives Compared
| Tucatinib | Verzenio | Kisqali |
|
|---|
| Tucatinib | Verzenio (abemaciclib) | Kisqali (ribociclib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer, Colorectal Cancer. tucatinib may also be used for purposes not listed in this medication guide. |
Prescription only
Verzenio (abemaciclib) is a targeted treatment that helps to reduce the growth and spread of cancer cells in the body. It may be used to treat HR+ HER2-, node-positive, early breast cancer at high... View more |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer. Kisqali may also be used for purposes not listed in this medication guide. |
Related suggestions Breast Cancer
|
|||||||||||||||
| More about Tucatinib | More about Verzenio (abemaciclib) | More about Kisqali (ribociclib) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Verzenio has an average rating of 8.2 out of 10 from a total of 25 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 4% reported a negative effect. |
Kisqali has an average rating of 8.5 out of 10 from a total of 28 ratings on Drugs.com. 81% of reviewers reported a positive effect, while 4% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
|
See also: Tucatinib side effects in more detail. |
See also: Verzenio side effects in more detail. |
See also: Kisqali side effects in more detail. |
||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Verzenio prices |
View all Kisqali prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Tukysa |
N/A |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
8.5 hours |
24.8 hours |
54.7 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 497 drugs are known to interact with Tucatinib:
|
A total of 342 drugs are known to interact with Verzenio:
|
A total of 720 drugs are known to interact with Kisqali:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
April 17, 2020 |
September 28, 2017 |
March 13, 2017 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.